Evidence map›Paper›PMID 42587382›Full record

ReviewClinical and translational science2026

Quantitative and Clinical Pharmacology Perspectives on Next-Generation Malaria Prevention Using Vaccines and Long-Acting Monoclonal Antibodies.

Sabiha R Mim, Leonardo C Xavier, Francine J Azeredo, Sihem Ait-Oudhia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sabiha R MimCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0009-0005-9359-8527
Leonardo C XavierCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0002-3101-4814
Francine J AzeredoCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0003-3625-0186
Sihem Ait-OudhiaQuantitative Pharmacology and Pharmacometrics (QP2), Merck & Co., Inc, Rahway, New Jersey, USA.ORCID 0000-0002-9794-8601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria remains a significant global health burden, particularly among pediatric populations in endemic regions. Recent advances in preventive interventions highlight the complementary roles of vaccines and long-acting monoclonal antibodies (mAbs) in reducing infection risk. Vaccines such as RTS,S/AS01 and R21/Matrix-M induce active immunity through polyclonal antibody and CD4

Indexed as

Antibodies, MonoclonalMalariaMalaria, FalciparumMalaria VaccinesAnimalsAntimalarialsHuman Challenge Trials as TopicHumansPlasmodium falciparumProtozoan ProteinsAntibodies, MonoclonalAntimalarialsMalaria VaccinesProtozoan Proteinscontrolled human malaria infection (CHMI)long‐acting monoclonal antibodiesmalaria preventionmodel‐informed drug developmentvaccines

Identifiers

PMID42587382
PMCPMC13469169

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.